Non fermentative Gram negative bacilli infections in a tertiary care rural hospital

Seema Bose*1, Atindra Krishna Ghosh2, Rekha Barapatre3

1Professor of Microbiology, Rural Medical College, Loni BK, Dist. Ahmednagar, Maharashtra – 413736, India
2Professor of Medicine, Rural Medical College, Loni BK, Dist Ahmednagar, Maharashtra – 413736, India
3Post graduate student of Microbiology, Rural Medical College, Loni BK, Dist. Ahmednagar, Maharashtra - 413736, India

*Correspondence Info:
Dr. Seema Bose
Professor of Microbiology
Rural Medical College, Loni BK,
Dist. Ahmednagar, Maharashtra – 413736, India.
Email – drseema11ghosh@gmail.com

Abstract

Introduction: Non fermentative Gram negative bacilli (NF GNB) are being increasingly isolated from patients admitted in hospitals. Most of these isolates are multidrug resistant (MDR).

Methods: Over a period of one year, all clinical samples were processed and NF GNB was identified up to species level following conventional method. Antibiotic sensitivity test of the isolates were done following clinical and laboratory standard institute (CLSI) guidelines.

Results: Out of 1498 clinical specimens, 320 (21.36%) isolates were identified as NF GNB. Maximum number of samples was blood, 90(28.12%), followed by pus, 84 (26.25%). Pseudomonas aeruginosa (P. aeruginosa) was the commonest isolate, 192 (60%), followed by Pseudomonas species (P. species), 58 (18.12%) & Acinetobacter baumannii (A. baumannii), 46(14.37%). All isolates were MDR and were sensitive to polymyxin B, colistin and tigecycline.

Conclusion: Multidrug resistant NF GNB was not uncommon in our hospital. All isolates were sensitive to polymyxin B, colistin and tigecycline. Indiscriminate use of antibiotics against these organisms should be avoided.

Keywords: Non fermentative; Multi drug resistant; Pseudomonas; Acinetobacter

1. Introduction

The non fermentative Gram negative bacilli (NF GNB) are aerobic and non spore forming microorganisms. They do not utilize carbohydrates or breakdown them through oxidative metabolic pathway. Previously NF GNB were considered to be non pathogenic and of very little significance. Recently, rate of infection by NF GNB is rising, especially in hospitalized and immunocompromised patients. NF GNB infection constitutes about one – fifth of all Gram negative bacilli infections. These organisms can remain viable on medical devices and are resistant to many commonly used antibiotics. Therefore, they play an important role in hospital acquired infection. Although, rate of isolation of NF GNB from clinical specimens is increasing rapidly, very few laboratories in India identify these organisms routinely. Sometimes, NF – GNB is difficult to identify phenotypically. Most of them are multidrug resistant (MDR).1 Malini et al2 from Karnataka, India observed 4.5 % infection rate of NF GNB in their hospital.

Therefore, the present study was conducted to identify NF GNB, isolated from clinical specimens, up to species level and to find out suitable antibiotics to treat such patients.
2. Material & Methods

2.1 Ethics committee approval – The study was approved by the Institutional ethical committee (Reference no – PMT/RMC/RC/ 2010/522). All the clinical samples received in the microbiology department were processed without delay following conventional methods. Urine samples were screened for significant bacteriuria (≥ 10^5 colonies/mL). Gram staining and culture were done from pus samples. The clinical samples were cultured on blood agar and MacConkey’s agar and incubated at 37°C for 24 – 48 hours aerobically. Battery of tests was done with the colony as per conventional methods.

Antibiotic sensitivity test was performed by using modified Kirby – Bauer disk diffusion method following clinical and laboratory standard institute (CLSI) guidelines. The antibiotic disks used for this study were following – ceftazidime (10 µg), Amikacin (30 µg), Netilmicin (30 µg), ciprofloxacin (5µg), ticarcillin (75 µg), cefepime (30 µg), piperacillin/tazobactam (100/10µg), Imipenem (10µg), aztreonam (30 µg), colistin (10 µg), polymyxin B (50 µg) and tigecycline (15 µg). MIC (minimum inhibitory concentration) of imipenem was also detected in resistant isolates. All antibiotic disks were obtained from Himedia pvt ltd, India and the E strip for MIC detection from AB BioMerieux.

The isolates from patient’s specimens were also clinically correlated by discussion with attending physician and by retrospective reference of the patient’s records. The symptoms and signs of infections, hematological and radiological findings and repeated isolation of same organisms from patient’s specimens were considered in support of clinical significance.

3. Observations & Results

A total of 1498 specimens, such as, blood, urine, pus etc were processed in the microbiology laboratory over a period of one year. Out of which, 320 (21.36%) NF GNB were isolated and identified up to species level. Organisms isolated were 192 (60%) Pseudomonas aeruginosa (P. aeruginosa), 58 (18.12%) Pseudomonas species (P. species), 11 (3.43%) Pseudomonas fluorescence (P. fluorescensce), 46 (14.37%) Acinetobacter baumannii (A. baumannii), 7 (2.18%) Acinetobacter lwoffi (A. lwoffi), 2 (0.62%) Alkaligenes faecalis (A. faecalis) and 1 (0.31%) Stenotrophomonas maltophilia (S. maltophilia). 3 (0.93%) of the NF GNB isolates could not be identified up to species level. (Table 1)

| Samples (Total & %) | P. aeruginosa | P. species | P. fluorescensce | A. baumannii | A. lwoffi | A. faecalis | S. maltophilia | Nil fermenter |
|---------------------|---------------|------------|------------------|--------------|-----------|------------|----------------|--------------|
| Pus (84, 26.25%)    | 45            | 19         | 8                | 10           | 1         | -          | -              | 1            |
| Blood (90, 28.12%)  | 71            | 5          | -                | 13           | 1         | -          | -              | -            |
| Urine (58, 18.12%)  | 33            | 7          | -                | 14           | 2         | -          | -              | 2            |
| Cerebrospinal fluid (12, 3.75%) | 2    | 4          | 1                | 3            | 1         | -          | 1              | -            |
| Sputum (16, 5%)     | 10            | 2          | 1                | 2            | 1         | -          | -              | -            |
| Vaginal swab (16, 5%) | 14          | 2          | -                | -            | -         | -          | -              | -            |
| Pleural fluid (12, 3.75%) | 2        | 8          | -                | 2            | -         | -          | -              | -            |
| Endotracheal tube (17, 5.31%) | 7      | 6          | 1                | 2            | 1         | -          | -              | -            |
| Stool (3, 0.93%)    | 1             | -          | -                | -            | 2         | -          | -              | -            |
| Catheter tip (5, 1.56%) | 4           | 1          | -                | -            | -         | -          | -              | -            |
| Throat swab (4, 1.25%) | 2            | 2          | -                | -            | -         | -          | -              | -            |
| Ascitic fluid (3, 0.93%) | 1           | 2          | -                | -            | -         | -          | -              | -            |
| Total (n = 320)     | 192 (60%)     | 58 (18.12%) | 11 (3.43%)       | 46 (14.37%)  | 7 (2.18%) | 2 (0.62%)  | 1 (0.31%)      | 3 (0.93%)    |

Maximum number of isolates were from blood samples, i.e. 90 (28.12%), followed by pus 84 (26.25%), urine 58 (18.12%) endotracheal tube aspiration, 16 (5%) sputum and vaginal swab each, 12 (3.75%) cerebrospinal fluid and pleural fluid each, 5 (1.56%) catheter tips, 4 (1.25%) throat swab and 3 (0.93%) stool and ascitic fluid each. (Table 1)


Table 2: Antibiotic sensitivity pattern of various clinical isolates.

| Antibiotics | P. aeruginosa (n = 192) | P. Species (n = 58) | P. Fluorescence (n = 11) | A. Baumannii (n = 46) | A. Iwoffi (n = 7) | S. Maltophilia (n = 1) | A. Faecalis (n = 2) | Nil Fermenter (n = 3) |
|-------------|-------------------------|---------------------|--------------------------|-----------------------|-----------------|------------------------|----------------------|----------------------|
| Ceftazidime | 11 (5.72%)              | 8 (13.79%)          | 3 (27.27%)               | 10 (21.73%)           | 0               | 0                      | 0                    | 0                    |
| Amikacin    | 42 (21.87%)             | 10 (17.24%)         | 2 (18.18%)               | 12 (26.06%)           | 4 (57.14%)      | 1 (100%)               | 1 (50%)              | 2 (66.66%)           |
| Netilmicin  | 25 (13.02%)             | 13 (27.08%)         | 2 (18.18%)               | 11 (23.91%)           | 3 (42.85%)      | 1 (100%)               | 2 (100%)             | 1 (33.33%)           |
| Ciprofloxacin| 21 (10.93%)             | 10 (17.24%)         | 3 (27.27%)               | 14 (30.43%)           | 3 (42.85%)      | 0                      | 1 (50%)              | 0                    |
| Ticarcillin | 9 (4.68%)               | 3 (5.17%)           | 2 (18.18%)               | 8 (17.39%)            | 2 (18.18%)      | 1 (100%)               | 0                    | 1 (33.33%)           |
| Piperacillin/ | 47 (24.47%)             | 23 (39.65%)         | 7 (63.63%)               | 21 (45.65%)           | 4 (57.14%)      | 1 (100%)               | 1 (50%)              | 2 (66.66%)           |
| Tazobactam  |                        |                     |                          |                       |                 |                        |                      |                      |
| Aztreonam   | 4 (2.08%)               | 4 (6.89%)           | 2 (18.18%)               | 2 (4.34%)             | 4 (57.14%)      | 1 (100%)               | 1 (50%)              | 2 (66.66%)           |
| Imipenem    | 86 (44.79%)             | 39 (67.24%)         | 8 (72.72%)               | 28 (60.86%)           | 5 (71.42%)      | 1 (100%)               | 2 (100%)             | 3 (100%)             |
| Polymyxin B | 192 (100%)              | 58 (100%)           | 11 (100%)                | 46 (100%)             | 7 (100%)        | 1 (100%)               | 2 (100%)             | 3 (100%)             |
| Colistin    | 192 (100%)              | 58 (100%)           | 11 (100%)                | 46 (100%)             | 7 (100%)        | 1 (100%)               | 2 (100%)             | 3 (100%)             |
| Tigecycline | 192 (100%)              | 58 (100%)           | 11 (100%)                | 46 (100%)             | 7 (100%)        | 1 (100%)               | 2 (100%)             | 3 (100%)             |

All the isolates were MDR. All imipenem resistant NF GNB (by disk diffusion method) showed high MIC values to imipenem. All the NF GNB, isolated from clinical samples was found susceptible to polymyxin B, colistin and tigecycline. (Table 2)

4. Discussion

NF GNB is rapidly emerging as important opportunistic pathogen, mainly in immunocompromised or hospitalized patients. These organisms are aerobic, non-spore bearing and do not breakdown carbohydrates as a source of energy, other than fermentation. They mainly cause hospital acquired infection. Indiscriminate use of antibiotics play a major role in development of resistance to commonly used antibiotics. Initial identification of NF GNB is done by absence of acid production in triple sugar iron (TSI) agar and no growth on MacConkey’s agar. Major laboratory tests to identify NF GNB are – Gram stain, Hugh – Leifson’s test, gelatin liquefaction, starch hydrolysis, urease production, nitrate reduction, indole test, hydrogen sulphide production, growth on 6.5% sodium chloride solution, pigment production, lysine decarboxylation and fermentation of glucose, lactose, maltose, Mannitol and xylose. Over a period of one year, we isolated 320 (21.36%) NF GNB out of 1498 clinical specimens. The most common isolate was P aeruginosa, i.e., 192 (60%) and P species, 58 (18.12%) followed by A baumannii, 46(14.37%). Siou Cling Su et al10 in their study, isolated approximately 15% NF GNB out of all Gram negative bacilli isolates. They did oligonucleotide array based test to identify NF GNB from clinical specimens and found that P aeruginosa was the commonest isolate, followed by Acinetobacter species. Our study was also similar to the study done by Malini et al2, i.e., 53.8% P aeruginosa and 22.2% A. baumannii isolates. Upgrade et al6 isolated 43% Pseudomonas species and 21% Acinetobacter species in their study.

We isolated maximum number of NF GNB from blood, i.e., 90(28.12%). Some other researchers isolated majority of non fermenters from pus and urine samples.
Multidrug resistance was considered when the organism was resistant to 3 or more classes of antibiotics.11 Antibiotic susceptibility pattern of NF GNB vary from country to country and from also different places within the same country.12 All of our NF GNB isolates were MDR. NF GNB has got a tendency for inherent or acquired drug resistance to the commonly used antibiotics.7 Upgrade et al6 observed 80% resistance of NF GNB to major antibiotics. Nicasio et al13 reported increasing resistance of NF GNB to commonly used antibiotics, including carbapenems, cephalosporin, penicillin, fluoroquinolones and amino glycosides. They also observed that isolates were mostly sensitive to polymyxin B. Some researchers reported that to treat NF GNB infection, some old antibiotics with more side effects were again in use.14 All our isolates were sensitive to polymyxin B, colistin and tigecycline. Colistin and polymyxin B has got side effects like renal toxicity (27 – 58%).15 Li et al16 and Falaqas et al17 also found usefulness of colistin and polymyxin B against MDR P. aeruginosa, A. baumannii and Klebsiella pneumoniae (K. pneumoniae) due to low resistance rate to this drug. They also advised judicious use of the antibiotics for infection caused by these 3 microorganisms.

Tigecycline (Gar 936) is a new glycopeptides derivative of tetracycline. It has a wide range of antibacterial activity, both against Gram positive and Gram negative bacteria.18 However, reports regarding resistance to colistin and tigecycline have been observed by some workers.19, 20 NF GNB is ubiquitously distributed in the environment. Their isolation from patient's samples should be clinically correlated to avoid unnecessary administration of antibiotics and thereby preventing the development of MDR strains. We included those cases in our study, in which, there were repeated isolation of same organism from repeat samples. Other inclusion criteria were presence of pus cells along with Gram negative bacilli in the stained smear of the clinical samples, evidence of mono microbial infection from sterile body fluid and radiological or hematological reports supporting infection. Symptoms and signs indicating infection were also taken into consideration.

5. Conclusion

NF GNB infection is emerging rapidly as major pathogens in health care settings. All infections by NF GNB should be clinically correlated. NF GNB develops resistance to commonly used antibiotics very fast. All our isolates were sensitive to polymyxin B; colistin and tigecycline. Careful administration of antibiotics should be applied, because these organisms have a tendency to develop resistance.

Acknowledgement

The authors wish to thank Pravara Institute of Medical Sciences, Loni for providing with the support for the study.

References

1. Lim VKE. Occurrence of Nonfermentative Gram negative bacilli in a Malaysian hospital. Singapore Med J 1985; 26:516 – 19.

2. Malini A, Deepa EK, Gokul BN, Prasad SR. Nonfermenting Gram negative bacilli infections in a tertiary care hospital in Kolar, Karnataka. Karnataka J Lab Physicians 2009; 1(2): 62 -6.

3. Chapter 7: Collee JG, Miles RS, Watt B. Test for identification of bacteria. In : Mackie and McCartney’s Practical Medical Microbiology 14th ed. JG Collee, AG Fraser, BP Marmion, A Simmons ,Editors. Churchill Livingstone: Indian Reprints; 2008. pp 131 – 49.

4. Performance standard for antimicrobial susceptibility testing; twenty first informational supplements (M 100 – S22)2012; 32(3): 62 – 69.

5. Koneman C, Allen SD, Janda WM et al. Non fermentative Gram negative bacilli. In: Colour Atlas and Text book of Diagnostic Microbiology. Lippincott publication; 1997. 5th ed. Pp 253 – 320.

6. Upgrade A, Prabhu N, Gopi V, Soundararajan N. Current status of antibiotic resistant non fermentative Gram negative bacilli among Nosocomial infections. Advances in Applied Science and Research 2012; 3(2): 738 – 42.

7. Enoch DA, Birkett CI, Ludlam HA. Non fermentative Gram negative bacteria. Int J Antimicrob agents 2007; suppl 3: 533 – 41.
8. Chapter 13: Overview of bacterial identification methods and strategies. In: Bailey and Scotts Diagnostic Microbiology 12th ed. Forbes AB, Sahm DF, Weissfeld AS, Editors. Mosby Elsevier international edition, 2007. pp 216 – 47.

9. Palleroni NJ. Family Pseudomoneraceae. In Kriey NR, Hikf G. Eds. Bergeys manual of systemic bacteriology. Baltimore: Williams and Maultans. 1984, (1): pp 141 – 219.

10. Cling Su S, Vaneechoutte M, Dijkshorn L, Wei YF, Chen YL, Chang TC. Identification of non fermenting Gram negative bacteria of clinical importance by an oligonucleotide array. *J Med Microbiol* 2009; 58(5): 596 – 605.

11. Souli M, Galani I, Giamarellou H. Emergence of extensively drug resistant and pan drug resistant Gram negative bacilli in Europe. *Euro surveill* 2008; 13(47). Pii: 19045.

12. Prasanth K, Badrinath S. In vitro susceptibility pattern of *Acinetobacter species* to commonly used cephalosporins, quinolones and aminoglycosides. *Indian J Med Microbiol* 2004; 22: 97 – 103.

13. Nicasio AM, Kuti JL, Nicolau DP. The current state of multi drug resistant Gram negative bacilli in North America. *Pharmaco therapy* 2008; 28 (2): 235 – 49.

14. Rice LB. Emerging issues in management of infections caused by multi drug resistant Gram negative bacteria. *Cleve Clin J Med* 2007; 74 (suppl 4): S12 – 12.

15. Michalopoulas A, Falagus ME. Colistin and polymyxin B in critical care. *Crit Care Clin* 2008; 24 : 377 – 391.

16. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multi resistant Gram negative bacteria. *Int J Antimicrob Agents* 2005; 25(1): 21 – 25.

17. Falagas ME, Biliziotis IA. Pan drug resistant Gram negative bacteria: the dawn of the post antibiotic era? *Int J Antimicrob Agents* 2007; 29(6): 630 – 6.

18. De A, Bindlish A, Kumar S, Mathur M. Vancomycin resistant *enterococci* in a tertiary care hospital in Mumbai. *Ind J Med Microbiol* 2009; 27: 375 – 76.

19. Antoniadou A, Kontopidou F, Poulakou G. Colistin resistant isolates of *Klebsiella pneumoniae* emerging in intensive care unit patient: first report of a multicolonial cluster. *J Antimicrobe Chemother* 2007; 59; 786 – 90.

20. Neonakis IK, Stylianou K, Daphnis E, Maraki S. First case of resistance to tigecycline by *Klebsiella pneumoniae* in a European university hospital. *Ind J Med Microbiol* 2011; 78 – 9.